Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
BACKGROUND:
Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we evaluated t…
Journal:
Authors:
- Jensen C,
- Madsen DH,
- Hansen M,
- Schmidt H,
- Svane IM,
- Karsdal MA,
- Willumsen N,
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients (1)
Background
Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we evaluated th…
Journal:
Authors:
- Jensen C,
- Madsen D,
- Hansen M,
- Schmidt H,
- Svane IM,
Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders
Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have bioma…
Journal:
Authors:
- Jensen C,
- Nielsen SH,
- Mortensen JH,
- Kjeldsen J,
- Klinge LG,
- Harling H,
- Jørgensen LN,
- Karsdal MA,
- Willumsen N,
- Leeming DJ,
Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities
Immuno-therapy has begun to revolutionize cancer treatment. However, despite the significant progress achieved in regard to the duration of clinical benefits, a substantial number of patients do not respond to these therapies. To improve the outcome of patients receiving immuno-therapy, there is a n…
Journal:
Authors:
- Willumsen N,
- Thomsen LB,
- Bager CL,
- Jensen C,
- Karsdal MA,